Adage Capital Partners
NGNE icon

Adage Capital Partners’s Neurogene NGNE Stock Holding History

Adage Capital Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41,900
Closed -$1.76M – 934
2024
Q3 		$1.76M Sell
41,900
-120,000
-74% -$4.65M ﹤0.01% 788
2024
Q2 		$5.89M Sell
161,900
-9,745
-6% -$344K 0.01% 690
2024
Q1 		$8.74M Buy
171,645
+36,064
+27% +$1.2M 0.02% 623
2023
Q4 		$2.63M Buy
135,581
+58,081
+75% +$832K 0.01% 730
2023
Q3 		$1.22M Buy
+77,500
New +$1.14M ﹤0.01% 758
2018
Q2 		– Sell
-25,000
Closed -$7.04M – 775
2018
Q1 		$7.04M Buy
25,000
+12,500
+100% +$3.45M 0.02% 608
2017
Q4 		$2.94M Hold
12,500
– – 0.01% 652
2017
Q3 		$3.55M Buy
+12,500
New +$3.59M 0.01% 645

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners's NGNE Position: Q4 2024 in Review

Adage Capital Partners sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 41,900 shares — an estimated $1.76M sold.

Adage Capital Partners first reported a position in NGNE in Q3 2017 and held it in 8 quarters. The position peaked at $8.74M in Q1 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • Adage Capital Partners reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • Adage Capital Partners sold 41,900 Neurogene shares in Q4 2024, an estimated $1.76M.
  • Adage Capital Partners first reported a position in Neurogene in Q3 2017 and held it in 8 quarters.
  • Adage Capital Partners's Neurogene position peaked at $8.74M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.